Clinical trial NCT06260618: Effect of Chitodex Gel in Tympanoplasty Surgery
Official title: A Single-blinded Randomised Trial Evaluating the Efficacy of Chitosan-dextran (Chitodex) Gel Versus Gelfoam Sponge Instillation Within the Middle Ear and External Auditory Canal During Tympanoplasty Surgery
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Tympanic Membrane Perforation
Tympanic Membrane Inflammation
Surgery
Otitis Media
Keywords: tympanic membrane
surgery
single blinded
chitogel
chitosan-dextran
otitis media
gelfoam
medical device
chitodex
myringoplasty
mastoidectomy
ossiculoplasty
Lead sponsor: Central Adelaide Local Health Network Incorporated
Sponsor class: OTHER_GOV
Collaborators: name: University of Adelaide
First posted: 2024-02-15
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Single blinded randomised clinical trial
Primary purpose: TREATMENT

Brief summary: The general purpose of this study is to compare Chitosan-dextran (Chitodex) gel versus current standard of care, Gelfoam, as a middle ear (ME) and external auditory canal (EAC) packing agent as part of tympanoplasty, ossiculoplasty and mastoidectomy procedures.

Detailed description: The general purpose of this study is to compare Chitosan-dextran (Chitodex) gel versus current standard of care, Gelfoam, as a middle ear (ME) and external auditory canal (EAC) packing agent as part of tympanoplasty procedures to close tympanic membrane perforations (TMP), or ossiculoplasty due to ossicular chain disruption and its sequelae, or mastoidectomy for Chromin Otitis Media (COM) or its sequelae eg cholesteatoma.

The investigators aim to compare the success rates of middle ear surgery between the two products. The ultimate goal is to identify the ME packing agent-of-choice to ensure TMP closure as well as minimal inflammation of the middle ear mucosa. The most critical measure of success during tympanoplasty surgery is the closure of a chronic, pre-existing TMP. As such, the primary outcome will be a measure of tympanic membrane closure. This is performed under direct vision during routine post-operative surveillance via the use of either a hand-held otoscope or an operating otologic microscope. The investigators will perform this check at 4 distinct time-points: 2 and 6 weeks post-op, 3 months post-op and 6 months post-op.

Chitosan-dextran gel is packaged within a syringe and has a cannula attached, much like the Gelfoam syringe system. Approx 3-5mL of product is applied during the surgery. Approx 2mL into the middle ear, as a support material for the graft. After graft suturing is complete, another 3mL (approx) is applied into the external ear canal as a packing agent. This is the same procedure as Gelfoam is currently used for this purpose.

The surgeon will administer the gel during the surgery as they would with the standard of care Gelfoam. The product comes in a sterile kit to be opened by Scrub Nurse.

Fidelity of the interventions is measured in several ways by the surgeon at the end of the operation. A good seal for the graft is always assessed for by the surgeon prior to completing any tympanoplasty. This is determined via any evidence of air escape from the middle ear when palpating the tympanic membrane and graft at the end of the procedure. A good seal indicates a well-positioned graft. The surgeon's operative notes will indicate this. The investigators will also obtain endoscopic images and videos at the end of procedure to assess positioning of the graft.

Eligibility criteria: Inclusion Criteria:

1. Individuals who have otoscopic evidence of tympanic membrane perforation that is also confirmed by tympanometry (Defined as a Type B tympanogram, with elevated EAC volume) AND

   1. The TM perforation is associated with at least 15dB of conductive hearing loss on the affected side AND
   2. Are indicated to undergo closure of the perforation via tympanoplasty surgery
2. OR Individuals who are indicated for ossiculoplasty due to ossicular chain disruption and its sequelae
3. OR Individuals who are indicated for mastoidectomy for COM or its sequelae eg cholesteatoma
4. Demonstrate healthy, dry middle ear mucosal cavities at time of surgery AND
5. Are 18 years of age or over AND
6. Are able to give written informed consent AND
7. Are committed to returning for post-operative assessments at 2 and 6 weeks post-op, 3-, and 6- months post-op

Exclusion Criteria:

1. Operative ear is the better or only hearing ear
2. The ear has evidence of cholesteatoma or other middle ear tumour during otoscopic examination
3. dysfunction during otoscopic and tympanometric examination
4. Known allergy to shellfish or ciprofloxacin antibiotics
5. Pregnant or breastfeeding
6. Hepatitis, HIV or any blood disorders
7. COVID-19 positive patients
8. Contra-indications for MRI

Primary outcomes:
measure: Number of participants with tympanic membrane closure
timeFrame: Pre-operatively, and 2 weeks, 6 weeks, 3 months and 6 months post-operatively
measure: rate of tympanic membrane closure
timeFrame: Pre-operatively, and 2 weeks, 6 weeks, 3 months and 6 months post-operatively
Secondary outcomes:
measure: Number of participants with improved hearing
timeFrame: Pre-operatively, and 2 weeks, 6 weeks, 3 months and 6 months post-operatively
measure: Number of participants with improved eardrum function
timeFrame: Pre-operatively, and 3 months and 6 months post-operatively
measure: Ease of use of product compared to active comparator - surgeon feedback
timeFrame: Once, on day of surgery (within 6 hours post-operatively)
measure: Time taken to complete surgery
timeFrame: Once, for the duration of the operation (hours)
measure: Number of Participants with improved quality of life
timeFrame: Pre-operatively, and 2 weeks, 6 weeks, 3 months and 6 months post-operatively
measure: Clearance of Chitodex gel from middle ear
timeFrame: 4 weeks post-operatively
Other outcomes:
Locations:
city: Adelaide
country: Australia
facility: The Queen Elizabeth Hospital
state: South Australia
city: North Adelaide
country: Australia
facility: The Memorial Hospital
state: South Australia
Study officials:
affiliation: Central Adelaide Local Health Network
name: Prof Peter-John Wormald, MD
role: PRINCIPAL_INVESTIGATOR
References: